Unlock instant, AI-driven research and patent intelligence for your innovation.

Preparation method of linezolid crystal form

A technology of linezolid and crystal form, applied in the field of preparation of linezolid crystal form, can solve the problems of harsh reaction conditions such as temperature, difficult industrial application, complicated reaction process, etc. good repeatability

Active Publication Date: 2018-01-02
JIANGSU HANSOH PHARMA CO LTD
View PDF5 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] The preparation method of linezolid crystal form III reported in the literature and patents often uses high boiling point reagent toluene as a solvent. Since toluene is a second-class solvent, there is a certain risk in using toluene as a solvent for the preparation of crystal forms in pharmaceutical development.
In addition, ethyl acetate is also used as a crystallization solvent in the prior art, but the reaction process is complicated when using this solvent to prepare crystal form III, and there are strict requirements on reaction conditions such as temperature, which is difficult for industrial application

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Preparation method of linezolid crystal form
  • Preparation method of linezolid crystal form
  • Preparation method of linezolid crystal form

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0019] Example 1 Preparation of crystalline form III of linezolid using ethyl acetate / n-heptane

[0020] Compound 1 (500 g, 1.48 mol) was added into ethyl acetate (15 L), heated to dissolve, and then the solution was poured into n-heptane (15 L) to cool and stir for 1 h to crystallize. After filtration, the resulting solid was dried under reduced pressure at 50°C to constant weight. The target product (468 g, off-white solid) was obtained with a yield of 93.6%, HPLC: 99.8%. After testing, its XRPD pattern is as follows figure 1 shown.

Embodiment 2

[0021] Example 2 Screening test for preparation conditions of linezolid crystal form III

[0022] The inventor further carried out a condition screening test for the optimal preparation conditions of the crystal form III. Except for the difference in the types of solvents in the following table, the rest of the test conditions were the same as in Example 1. After the test was completed, the yield of the crystal form III was the same as that of the product The purity results are shown in the table below:

[0023] solvent

[0024] From the screening of preparation conditions, it can be seen that the composite solvent is superior to single solvent crystallization in terms of product yield and purity.

experiment example 1

[0025] Experimental Example 1 Stability Experiment

[0026] Instrument model: D / Max-RA Japan Rigaku X-ray powder diffractometer

[0027] Rays: monochromatic Cu-Kα rays

[0028] Scanning mode: θ / 2θ, scanning range: 3-45°

[0029] Temperature range: 294K Voltage: 40KV

[0030] The comparison of X-ray diffraction data is shown in Table 1.

[0031] Table 1 X-ray diffraction data comparison table of accelerated stability test samples

[0032]

[0033] Experimental conclusion: after 6 months of accelerated experimentation, the X-ray diffraction spectrum is consistent with the initial data, and no crystal transformation occurs, indicating that the crystal form provided by the present invention has good stability.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a preparation method of linezolid crystal form. Specifically, the present invention relates to formula (1) compound (S)-N-[[3-(3-fluoro-4-(4-morpholinyl) phenyl)-2-oxo-5-oxazolidinyl A method for preparing ]methyl]acetamide crystal form III, that is, linezolid crystal form III, the method comprises adding linezolid to a complex solvent for crystallization, drying to obtain the target crystal form. The crystal form III prepared by the invention has stable properties, good repeatability and is suitable for drug development.

Description

technical field [0001] The present invention relates to linezolid (S)-N-[[3-(3-fluoro-4-(4-morpholinyl)phenyl)-2-oxo-5-oxazolidinyl]methyl]ethyl Preparation method of amide crystal form III. Background technique [0002] Linezolid (1inezolid, trade name Zyvox) is a new type of oxazolidinone synthetic antibacterial drug developed and produced by Pharmacia & Upjohn Company of the United States (later acquired by Pfizer). The FDA approved the drug on April 18, 2000. . This product is the first drug approved in the United States for the treatment of methicillin-resistant Staphylococcus aureus infection in 40 years. [0003] According to current patent reports, linezolid has 14 crystal forms. Pharmacia & Upjohn first disclosed linezolid crystallization in CN101353313A on 1998-10-13, crystal form I; CN1221547C (Pharmacia & Upjohn) reported crystal form II; WO2005035530A1 (SYMED LABS LIMRRED) reported crystal form III; WO2006110155A (Teva) Forms V to XVIII are reported, as well...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): C07D263/20
Inventor 金磊李广猛金爱民丁磊
Owner JIANGSU HANSOH PHARMA CO LTD